As a strategy to be the leading company in the development of innovative diagnostic solutions, non-invasive, accurate and cost-effective, allowing enjoy better health, we are also working on the development of other algorithms MBDAA for other cancers taking advantage of the methodology and knowledge gained in the development of the algorithms for Lung Cancer, Ovarian Cancer, Prostate Cancer and Cancer of Unknown Primary.

In this sense we have 5 algorithms for Bladder, Breast, Colorectal, Head & Neck and Liver in phase 2 (phase in which it is the test designed and developed) of the 4 phases that exist (Research, Assay Development, Testing, Validation of R&D and Market Ready).

Moreover, we have also working in Cervix, Gastric, Kidney, Pancreatic, Testicular, Thyroid and Uterine Cancers in phase 1 (phase of research and literature search on novel tumor markers related to these pathologies).